國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance to targeted therapies in ...

Prosperi, Jenifer R.

Resistance to targeted therapies in breast cancer

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance to targeted therapies in breast canceredited by Jenifer R. Prosperi.
其他作者:	Prosperi, Jenifer R.
出版者:	Cham :Springer International Publishing :2017.
面頁冊數:	xv, 184 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	BreastCancer
電子資源:	http://dx.doi.org/10.1007/978-3-319-70142-4
ISBN:	9783319701424$q(electronic bk.)

Resistance to targeted therapies in breast cancer
Resistance to targeted therapies in breast cancer[electronic resource] /edited by Jenifer R. Prosperi. - Cham :Springer International Publishing :2017. - xv, 184 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.162196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling) We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.

ISBN: 9783319701424$q(electronic bk.)

Standard No.: 10.1007/978-3-319-70142-4doiSubjects--Topical Terms:

222784
Breast
--Cancer

LC Class. No.: RC280.B8

Dewey Class. No.: 616.99449061

Resistance to targeted therapies in breast cancer
LDR:02091nmm a2200325 a 4500 001 525634
003 DE-He213
005 20171204113727.0
006 m d
007 cr nn 008maaau
008 180918s2017 gw s 0 eng d
020 $a 9783319701424$q(electronic bk.)
020 $a 9783319701417$q(paper)
024 7 $a 10.1007/978-3-319-70142-4 $2 doi
035 $a 978-3-319-70142-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.B8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99449061 $2 23
090 $a RC280.B8 $b R433 2017
245 0 0 $a Resistance to targeted therapies in breast cancer $h [electronic resource] / $c edited by Jenifer R. Prosperi.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xv, 184 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.16
505 0 $a Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
520 $a We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling) We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
650 0 $a Breast $x Cancer $x Chemotherapy. $3 222784
650 0 $a Drug resistance in cancer cells. $3 281104
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Cancer Research. $3 273660
700 1 $a Prosperi, Jenifer R. $3 798027
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 711051
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-70142-4
950 $a Biomedical and Life Sciences (Springer-11642)